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Therapeutic use of radiation for selective destruction of
tumors is a well-established method currently available.
This kind of treatment combines advantages of tumor
targeting and systemic administration. The possibility of
use radiopharmaceuticals either for curative or for pallia-
tive purposes enlarge its therapeutic possibilities.
Aim: In this work we synthesize and evaluate the ligand
polyethyleneimine functionalized with methylene phos-
phonate groups (PEI-MP), through an APD by a Mannich
type reaction the biodistribution in animal models of hu-
man osteosarcoma, after labelled with 99mTc, 117mSn,
186Re and 188Re.
Materials and methods: Normal Wistar rats were injected
in the tail vein, with an activity of 11-13 MBq 117mSn-PEI-
MP (20 rats), 186Re-PEI-MP (22 rats)186ReO4- (8 rats),
99mTc-PEI-MP (5 rats). A group of 5 CD1 rats were also
used, because gallbladder, in order to evaluate enterohep-
atic cycle. Normal balb-c mice were also injected with
188Re-PEI-MP (20 mice) and 188ReO4- (20 mice) respec-
tively. We also injected with the same tracers balb-c nude
mice with human osteosarcoma (35 mice) and bladder (10
mice) xenotransplante. Half of them were sacrificed 2.5 h
after injection and the others after 4 h. The organs were
counted in a well counter to determine the biodistibution.
Absorbed doses in the main organs were then calculated
according to the MIRD recommendation using OLINDA
software.
Results and Discussion: PEI-MP shows high dose for blad-
der and kidney for the tested radionuclides (99mTc,
117mSn, 186Re). Heart shows also a considerable dose.
Perenate shows lower doses for all the analyzed organs
maintaining bladder and kidneys as target organs. This
results are consistent with biodistibution which show
moderate reticuloendothelial uptake, reasonable bone-
uptake and considerable uptake in the bladder wall. At 4 h
186Re-PEI-MP shows rapid clearance of all organs had
taken place as confirmed by the 2.5 h study which indi-
cated considerable and early excretion in the urine and
little bone uptake. 186ReO4- showed at 4 h uptake in the
stomach, bladder and urine. As expected doses for 99mTc
are much lower, however the bladder is the target organ.
The normal biodistribution of 188ReO4- shows at 4 hours
high uptake by the in the stomach, bladder, thyroid and
urine. The absorbed doses are very low. The normal 188Re-
PEI-MP shows high dose for bladder, kidney and lung.
The absorbed doses are also very low. The 188ReO4-
biodistribution at animals with osteosarcoma shows a very
high uptake by thyroid, being the absorbed doses at a low
level. The 188Re-PEI-MP at animals with osteosarcoma
shows the maximum uptake at urinary bladder wall, be-
sides its small uptake by the tumor. At animals with blad-
der cancer shows an improve of uptake by the tumor.
Conclusions: The results obtained with different radio-
nuclides show for the cell lines tested they give different
adsorbed dose. This information in very important when
metabolic radiotherapy is considered.
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Introdução: A 18F-Fluoro-desoxiglicose (18F-FDG) é
utilizada por rotina no estudo de diversas neoplasias cujas
células tumorais apresentem elevada actividade metabólica
glicolítica. Contudo, reconhece-se que a 18F-FDG está
longe de ser um radiofármaco específico para doenças
neoplásicas malignas. Existe, assim, a necessidade cres-
cente de radiofármacos para tomografia por emissão de
positrões (PET) que se aproximem da complexa biologia
dos tumores.
Com vista ao contínuo desenvolvimento dos métodos de
imagem molecular, foi introduzido o 18F-Fluoreto de Sódio
(18F-FNa) na prática clínica do nosso Serviço. A decisão
da aplicação deste radiofármaco inicialmente em doentes
com carcinoma da mama deve-se ao comportamento bioló-
gico ambíguo das suas metástases ósseas. Pode tratar-se
de metástases predominantemente líticas, geralmente com
intensa captação de 18F-FDG ou de metástases predo-
minantemente blásticas, com ausente ou baixa captação
de 18F-FDG.
Objectivos: Avaliar a utilidade clínica da PET com 18F-
